Get the Stockscreener App
3.44
5.85%
0.19
After Hours:
3.38
-0.06
-1.74%
X 4 Pharmaceuticals Inc stock is traded at $3.44, with a volume of 792.97K.
It is up +5.85% in the last 24 hours and down -7.03% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.25
Open:
$3.25
24h Volume:
792.97K
Relative Volume:
1.33
Market Cap:
$300.78M
Revenue:
$33.98M
Net Income/Loss:
$-95.10M
P/E Ratio:
-0.3438
EPS:
-10.0072
Net Cash Flow:
$-106.13M
1W Performance:
+8.86%
1M Performance:
-7.03%
6M Performance:
-18.68%
1Y Performance:
-68.97%
1-Day Range:
$3.20
$3.44
1-Week Range:
$3.10
$3.5599
52-Week Range:
$1.35
$12.55
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.44 | 284.17M | 33.98M | -95.10M | -106.13M | -10.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - TradingView
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView
EMA backs potential first WHIM treatment in EU after 60% infection drop - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
X4 Pharmaceuticals (XFOR) Price Target Increased by 16.67% to 9.52 - Nasdaq
XFOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ETF Watch: How much upside does X4 Pharmaceuticals Inc haveJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Layoff Tracker: BMS, Catalent Further Whittle Workforces - BioSpace
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Ellerson Group Inc. ADV - MarketBeat
Why X4 Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Final Week & Verified Chart Pattern Trade Signals - mfd.ru
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and SchizophreniaA New Chemical Entity Opening New Horizons in Psychiatric Innovation - Morningstar
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance Singapore
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded by Zacks Research to Hold Rating - MarketBeat
AI Stocks: Will CADL stock go up in YEAR2025 Risk Factors & Precise Trade Entry Recommendations - baoquankhu1.vn
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times
Can X4 Pharmaceuticals Inc. lead its sector in growthPortfolio Gains Summary & AI Based Trade Execution Alerts - mfd.ru
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Is X4 Pharmaceuticals Inc. forming a bullish divergenceWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
ROSEN, A LEADING LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionINO - TMX Newsfile
How X4 Pharmaceuticals Inc. stock trades before earningsQuarterly Market Review & Long-Term Capital Growth Strategies - mfd.ru
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Wealthfront Advisers LLC - MarketBeat
115,028 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Sound Shore Management Inc CT - MarketBeat
Biopharma company Ligand to reveal 2025 results Feb. 26 - Stock Titan
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Viking Therapeutics, Inc. SEC 10-K Report - TradingView
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft - MarketBeat
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by First National Trust Co - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
New molluscum treatment YCANTH reaches Japanese patients after Phase 3 trial - stocktitan.net
Insider Returns Down To US$57k As X4 Pharmaceuticals' Stock Dips 11% - simplywall.st
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Buy" by Brokerages - MarketBeat
X4 Pharmaceuticals: Commercial Execution Takes Center Stage - AD HOC NEWS
Aug Gainers: Can X4 Pharmaceuticals Inc sustain earnings growthWall Street Watch & Entry Point Confirmation Alerts - baoquankhu1.vn
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Top Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price - simplywall.st
What is the fair value of X4 Pharmaceuticals Inc. stock nowMarket Sentiment Report & Community Consensus Picks - mfd.ru
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Business Wire
Prescription Drug Costs - Britannica
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 - Yahoo Finance
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $4.92 Consensus PT from Brokerages - Defense World
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $34.50 Average PT from Brokerages - Defense World
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Moving Averages: How much upside does X4 Pharmaceuticals Inc have2025 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):